EUR 0.08
(-2.44%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 12.21 Million EUR | -46.3% |
2022 | 22.5 Million EUR | -21.1% |
2021 | 28.52 Million EUR | -5.46% |
2020 | 30.17 Million EUR | -18.05% |
2019 | 36.81 Million EUR | -9.96% |
2018 | 40.89 Million EUR | 111.26% |
2017 | 19.35 Million EUR | -68.15% |
2016 | 60.77 Million EUR | 31.41% |
2015 | 46.24 Million EUR | -24.34% |
2014 | 61.12 Million EUR | -24.89% |
2013 | 81.38 Million EUR | 89.9% |
2012 | 42.85 Million EUR | 58.54% |
2011 | 27.03 Million EUR | 33.2% |
2010 | 20.29 Million EUR | 7.21% |
2009 | 18.93 Million EUR | 23.43% |
2008 | 15.33 Million EUR | -17.1% |
2007 | 18.5 Million EUR | 48.53% |
2006 | 12.45 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.28 Million EUR | 0.0% |
2023 Q2 | 7.83 Million EUR | 0.0% |
2023 Q4 | 5.06 Million EUR | 0.0% |
2023 FY | 12.08 Million EUR | -46.3% |
2022 FY | 22.5 Million EUR | -21.1% |
2022 Q2 | 13.63 Million EUR | 0.0% |
2022 Q4 | 8.86 Million EUR | 0.0% |
2021 Q2 | 15.07 Million EUR | 0.0% |
2021 Q4 | 13.36 Million EUR | 0.0% |
2021 FY | 28.52 Million EUR | -5.46% |
2020 FY | 30.17 Million EUR | -18.05% |
2020 Q4 | 16.37 Million EUR | 0.0% |
2020 Q2 | 13.83 Million EUR | 0.0% |
2019 Q2 | 16.6 Million EUR | 0.0% |
2019 Q4 | 19.61 Million EUR | 0.0% |
2019 FY | 36.81 Million EUR | -9.96% |
2018 Q2 | 18.29 Million EUR | 0.0% |
2018 Q4 | 22.59 Million EUR | 0.0% |
2018 FY | 40.89 Million EUR | 111.26% |
2017 Q4 | 35.11 Million EUR | 0.0% |
2017 FY | 19.35 Million EUR | -68.15% |
2017 Q2 | 15.76 Million EUR | 0.0% |
2016 Q4 | 43.23 Million EUR | 0.0% |
2016 Q2 | 17.53 Million EUR | 0.0% |
2016 FY | 60.77 Million EUR | 31.41% |
2015 FY | 46.24 Million EUR | -24.34% |
2015 Q4 | 21.64 Million EUR | 0.0% |
2015 Q2 | 24.59 Million EUR | 0.0% |
2014 Q4 | 30.1 Million EUR | 0.0% |
2014 Q2 | 31.01 Million EUR | 0.0% |
2014 FY | 61.12 Million EUR | -24.89% |
2013 Q2 | 44.77 Million EUR | 0.0% |
2013 Q4 | 36.61 Million EUR | 0.0% |
2013 FY | 81.38 Million EUR | 89.9% |
2012 Q1 | 10.71 Million EUR | 0.0% |
2012 FY | 42.85 Million EUR | 58.54% |
2012 Q4 | 20.22 Million EUR | 88.73% |
2012 Q2 | 10.71 Million EUR | 0.0% |
2012 Q3 | 10.71 Million EUR | 0.0% |
2011 Q4 | 10.71 Million EUR | 58.54% |
2011 Q1 | 6.75 Million EUR | 0.0% |
2011 Q2 | 6.75 Million EUR | 0.0% |
2011 FY | 27.03 Million EUR | 33.2% |
2011 Q3 | 6.75 Million EUR | 0.0% |
2010 FY | 20.29 Million EUR | 7.21% |
2010 Q2 | 5.07 Million EUR | 0.0% |
2010 Q1 | 5.07 Million EUR | 0.0% |
2010 Q3 | 5.07 Million EUR | 0.0% |
2010 Q4 | 6.75 Million EUR | 33.2% |
2009 Q1 | 4.73 Million EUR | 0.0% |
2009 FY | 18.93 Million EUR | 23.43% |
2009 Q3 | 4.73 Million EUR | 0.0% |
2009 Q2 | 4.73 Million EUR | 0.0% |
2009 Q4 | 5.07 Million EUR | 7.21% |
2008 Q4 | 4.73 Million EUR | 585.51% |
2008 FY | 15.33 Million EUR | -17.1% |
2008 Q1 | -974.75 Thousand EUR | 0.0% |
2008 Q2 | -974.75 Thousand EUR | 0.0% |
2008 Q3 | -974.75 Thousand EUR | 0.0% |
2007 Q3 | -364.75 Thousand EUR | 0.0% |
2007 Q4 | -974.75 Thousand EUR | -167.24% |
2007 FY | 18.5 Million EUR | 48.53% |
2007 Q2 | -364.75 Thousand EUR | 0.0% |
2007 Q1 | -364.75 Thousand EUR | 0.0% |
2006 Q4 | -364.75 Thousand EUR | -128.68% |
2006 FY | 12.45 Million EUR | 0.0% |
2006 Q3 | -159.5 Thousand EUR | 0.0% |
2006 Q2 | -159.5 Thousand EUR | 0.0% |
2006 Q1 | -159.5 Thousand EUR | 0.0% |
2005 Q4 | -159.5 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Nicox S.A. | -11.5 Million EUR | 206.181% |
European Medical Solutions | 13.64 Million EUR | 10.5% |
FERMENTALG | 12.34 Million EUR | 1.053% |
argenx SE | 1.34 Billion EUR | 99.09% |
BioSenic S.A. | 7.58 Million EUR | -61.071% |
Celyad Oncology SA | 8.49 Million EUR | -43.863% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | 32.095% |
Onward Medical N.V. | 20.64 Million EUR | 40.838% |
PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 51.117% |
Financière de Tubize SA | 114.38 Thousand EUR | -10577.6% |
UCB SA | 2.94 Billion EUR | 99.585% |